Oncogenic Chromatin Remodeling and Anticancer Mechanisms
致癌染色质重塑和抗癌机制
基本信息
- 批准号:10646923
- 负责人:
- 金额:$ 45.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-08 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:ARID1A geneAntineoplastic AgentsCCI-779Cancer BiologyCancer PatientChromatinChromatin Remodeling FactorClinicalComplexDataDevelopmentDiseaseFDA approvedFRAP1 geneGenetic TranscriptionGrowthHumanKnowledgeLeadMalignant NeoplasmsMediatingMolecularOncogenicOncologyOutcomePathway interactionsPharmaceutical PreparationsPhosphorylationPhysiologyPlayProtein KinaseProteinsPublishingRegulationResistanceRoleSWI/SNF Family ComplexSerineSignal PathwaySignal TransductionSirolimusSomatic MutationTestingTherapeuticTumor Suppressor Proteinsanti-cancercancer therapycancer typechromatin remodelingepigenetic regulationimprovedin vivoinhibitorpublic health relevanceresponsetargeted cancer therapytargeted treatmenttherapy resistanttreatment responsetumortumorigenesis
项目摘要
ABSTRACT
The SWI/SNF chromatin remodeling complexes impart epigenetic regulation and control accessibility of
chromatin to transcriptional machineries. Chromatin remodeling plays important roles in normal physiology and
diseases, particularly cancer. ARID1A is a component of the BAF SWI/SNF complex and a major tumor
suppressor. ARID1A is inactivated by somatic mutations in a wide spectrum of cancer types. Despite the
apparent importance of SWI/SNF chromatin remodelers in cancer, their regulation by growth and oncogenic
signals remains not well understood. mTOR complex 1 (mTORC1) is a conserved protein kinase and a central
growth controller. mTORC1 is an oncogenic driver and the target of US FDA-approved oncology drugs
rapamycin and rapamycin analogs. Our preliminary data revealed that mTORC1 promotes proteasomal
degradation of ARID1A protein. Moreover, ARID1A plays an important role in therapeutic response and
resistance to mTORC1 inhibitors. Because mTOR pathway is estimated to be activated in nearly half of all human
tumors, mTOR-dependent degradation represents a common mechanism to inactivate the ARID1A tumor
suppressor in cancer. Therefore, it is important to understand the underlying regulatory mechanisms and its role
in cancer biology and therapy. There are two specific aims in this application: Aim 1 will dissect the molecular
mechanism by which mTORC1 regulates ARID1A and oncogenic chromatin remodeling. Aim 2 will investigate
the significance of mTORC1-dependent ARID1A regulation in tumorigenesis and anticancer drug response. Our
studies are anticipated to fill a knowledge gap in the regulation of the ARID1A tumor suppressor in tumorigenesis
and anticancer drug response/resistance. If successful, this project could lead to better strategies to target mTOR
pathway, improving clinical outcomes for cancer patients.
摘要
SWI/SNF染色质重塑复合体具有表观遗传调控作用
染色质到转录机器。染色质重塑在正常生理和免疫反应中起重要作用
疾病,尤其是癌症。ARID1A是BAF SWI/SNF复合体的组成部分,是一种主要的肿瘤
抑制者。ARID1A在广泛的癌症类型中被体细胞突变失活。尽管
SWI/SNF染色质重构体在癌症中的重要性及其对生长和致癌的调节
信号仍然没有被很好地理解。MTOR复合体1(MTORC1)是一种保守的蛋白激酶,是一种中枢蛋白。
增长控制器。MTORC1是致癌驱动因素,也是美国FDA批准的肿瘤药物的靶点
雷帕霉素和雷帕霉素类似物。我们的初步数据显示mTORC1促进蛋白酶体
ARID1A蛋白的降解。此外,ARID1A在治疗反应和
对mTORC1抑制剂的耐药性。因为据估计,在近一半的人类中,mTOR通路被激活
肿瘤,mTOR依赖的降解是ARID1A肿瘤失活的常见机制
癌症的抑制者。因此,重要的是要了解潜在的监管机制及其作用
在癌症生物学和治疗方面。在这一应用中有两个特定的目标:目标1将剖析分子
MTORC1调节ARID1A和致癌染色质重塑的机制。AIM 2将调查
依赖mTORC1的ARID1A调控在肿瘤发生和抗癌药物反应中的意义我们的
研究有望填补ARID1a肿瘤抑制因子在肿瘤发生中的调控知识空白
和抗癌药物反应/耐药性。如果成功,这个项目可能会导致针对mTOR的更好战略
途径,改善癌症患者的临床结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN ZHENG其他文献
STEVEN ZHENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN ZHENG', 18)}}的其他基金
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
氨基酸-Rab1A 营养信号在血糖稳态调节中的作用
- 批准号:
10461838 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
氨基酸-Rab1A 营养信号在血糖稳态调节中的作用
- 批准号:
10266843 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
氨基酸-Rab1A 营养信号在血糖稳态调节中的作用
- 批准号:
10684889 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
mTOR 激酶抑制剂在结直肠癌中的作用机制
- 批准号:
8761387 - 财政年份:2013
- 资助金额:
$ 45.31万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 45.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 45.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 45.31万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 45.31万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 45.31万 - 项目类别:














{{item.name}}会员




